1. Fourth Quarter and Year
End 2012 Financial
Results Conference Call
February 28, 2013
2. Forward-looking Statements
Forward-looking Statements
Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to,
statements regarding expected gain of future market share, product sales growth, synergies, cash flow initiatives and
objectives and product approvals and launches. Forward-looking statements may be identified by the use of the words
“anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,”
or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs
of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and
uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange
Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and
the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update
any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect
actual outcomes.
Non-GAAP Information
To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the
company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up,
amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair
value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development
("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and
other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest,
loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and
adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making,
forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management
intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends
for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the
information is not necessarily comparable to other companies and should be considered as a supplement to, not a
substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
1
3. Agenda
1. Fourth Quarter & Year End 2012 Results
2. Operations Update
3. Financial Update
2
4. Fourth Quarter and Year End 2012
Results
Q4 2012 % 2012 %
Product Sales $947 M 45% $3,310 M 47%
Total Revenue $986 M 43% $3,547 M 44%
Cash EPS $1.22 30% $4.51 54%
Cash EPS Excluding
Medicis interest $1.34 43% $4.63 58%
expense
Adjusted Cash Flow
from Operations $423 M 67% $1,294 M 40%
3
5. 2012 Organic Growth
Same Store Sales*
Q4 2012 FY 2012
U.S. Derm/Promoted 17% 32%
U.S. Neuro 3% -4%
Canada / Australia 1 -12% -1%
Emerging Markets 12% 11%
Total 7% 8%
Pro Forma*
Q4 2012 FY 2012
U.S. Derm/Promoted 15% 25%
U.S. Neuro 3% -4%
Canada / Australia 2 -6% 1%
Emerging Markets 15% 13%
Total 9% 10%
* Adjusts for the impact of foreign exchange, acquisitions, divestitures/discontinuations, and includes JV revenues
1 Excluding Cesamet, the Canadian / Australian segment delivered Q4 5% organic growth (same store) and 6% (pro forma)
2 Excluding Cesamet, the Canadian / Australian segment delivered 2012 12% organic growth (same store) and 9% (pro forma) 4
6. Adjusted Cash Flow From Operations
$423
$322 $308 Excluded Items:
• Legal Settlements
• Restructuring/Acquisition
$241 Related Costs
• Tax Benefit from Stock Options
• Effect of ASC 470-20
1st Qtr* 2nd Qtr* 3rd Qtr 4th Qtr
Total 2012 Adjusted Cash Flow from Operations = $1.3 Billion
* Includes $66M Q1 dermatology divestitures and $45M Q2 milestone payment from GSK 5
7. 2012 Performance v. Guidance
Original Expectations Final Results
Revenue $3.1-$3.4 billion Revenue $3.5 billion
Cash EPS $3.95 - $4.20 Cash EPS $4.51
>$1.2 billion in Adjusted $1.3 billion in Adjusted
Cash Flow from Cash Flow from
Operations Operations
Organic Growth:
8% same store sales
10% pro forma
6
8. Top Performing Units in 2012
Poland
Market shrank 6% while Valeant grew 3%
Fastest growing pharmaceutical company in Poland; 1 of only 2 pharmaceutical
companies that delivered positive organic growth in 2012
Continue to gain market share as the overall Polish market returns to growth in 2013
South East Asia/South Africa
Delivered growth of 20% in constant currency
Both operations realize operating margins above 40%
U.S. Neurology & Other
After 6 quarters of decreases, delivered positive growth in Q412
Wellbutrin XL scripts have now leveled off; expect growth in products sales in 2013
U.S. Dermatology
Double digit growth in key Rx dermatology brands - Elidel, Zovirax, Xerese, Acanya,
Retin–A Micro
Other non-dermatology Rx business units also grew double digit - OraPharma,
ophthalmology, podiatry, aesthetics, consumer
Mexico
Delivered greater than 10% organic growth (pro forma)
Successfully added Atlantis acquisition to the portfolio 7
9. Other Business Updates
Business Development
Natur Produkt closed February 1
Acquired OTC assets from Lek-am in Poland February 12
Acquired Targretin from Eisai February 21
Medicis Integration Update
Integration on track – pursuing legal / R&D synergies
Sales force now fully trained and back in the field
Continue to see more upsides than downsides to original deal model
R&D / Product Updates
Luliconazole PDUFA date set for December 11, 2013
Dysport launched in Canada
Efinaconazole on track for May 23 PDUFA date
2 Emervel fillers to be filed in 2013
MetroGel 1.3% Hydrogel (Bacterial Vaginosis) to be filed 1H 2013
We will wait until Q1 2013 conference call to update financial
guidance 8
13. Q4 Medicis Project Related Costs
($ in millions)
Restructuring Related Costs Amount Paid
Severance Payments $78.0
Acquisition Related Costs Paid to 3rd Parties $23.7
Integration Related Consulting, Duplicative
Labor, Transition Services, and Other $3.5
Costs Incurred to date to Achieve Synergies $105.2
Pre-acquisition Related Costs Amount Paid
Stock Based Compensation 1 $134.7
Medicis Advisory & Legal Fees $47.0
Total $181.7
1Accelerated vesting of Medicis stock based compensation of $76M expensed and paid upon closing and payment of
Medicis stock appreciation rights and other compensation of $58M that was accrued by Medicis prior to close and paid
post-close 12
14. 2012 Revenue Bridge
$1,023 $35 $161 $39 $101
$327
$3,547
$2,463
2011 Rev B ase Growt h A cquisit ions One-Tim ers* Generics Divest itures Foreign Exchange 2012 Rev
* One-time items Include incremental revenue received from one-time items of $111M received in 2012 over
$76M received in 2011
13
15. Cash Flow Initiatives
We have set working capital targets for each
business unit
We are diligently tracking all restructuring costs
More disciplined approach for the deal model and restructuring
efforts
We are performing monthly working capital reviews
with each unit
Cash Flow objectives have been built into the GM’s
compensation structure
14
16. Fourth Quarter and Year
End 2012 Financial
Results Conference Call
February 28, 2013